Sakigake designation (Japan)
Japan's fast lane for innovative medicines developed there first: a designated drug gets priority consultation, a six-month review instead of twelve, and a price premium, in return for early development in Japan.
Overview
Japan, ministerial scheme made statutory in 2019. The Sakigake ('pioneer') designation system was launched by the Ministry of Health, Labour and Welfare as a pilot in 2015 under the Strategy of Sakigake and was written into the Pharmaceuticals and Medical Devices Act by the 2019 amendment, taking effect in September 2020. Primary text: the PMDA's English description.
How it works: a candidate must be innovative in mechanism, target a serious disease, show prominent effectiveness in early trials, and be developed in Japan ahead of or alongside the rest of the world, with the sponsor intending to file first in Japan. Designated products receive prioritised consultation, pre-submission review of data, a target review period of six months rather than twelve, a dedicated review manager and, on approval, a price premium under the National Health Insurance rules and an extended re-examination period. Several oncology products, including cell therapies and targeted agents, have been designated.
Why it exists and the arguments: Japan created it to end the 'drug lag' in which medicines reached Japanese patients years after the United States and Europe, by rewarding companies that develop there first rather than last. Designations remain few, and critics note that the condition of first filing in Japan limits it to products with Japanese origins or strong local strategies. It is the counterpart of the FDA's Breakthrough Therapy designation and the EMA's PRIME scheme, and it sits alongside Japan's conditional early approval system for drugs where confirmatory trials are hard to run.
Similar pages
not linked directly; found by shared links- TermChina Drug Administration Law (2019) and expedited pathways
Shares Conditional marketing authorisation (EU), Breakthrough Therapy / Priority Review / Priority Voucher, Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Accelerated approval and the tag law.
- TermFDASIA 2012 and the origins of the expedited programmes
Shares Fast Track and RMAT designations, Breakthrough Therapy / Priority Review / Priority Voucher, Accelerated approval, Regulatory divergence between regions and the tag law.
- TermILAP (Innovative Licensing and Access Pathway)
Shares Fast Track and RMAT designations, Breakthrough Therapy / Priority Review / Priority Voucher, Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Regulatory divergence between regions and the tag law.
- TermRegulation (EC) No 726/2004: the EU centralised procedure
Shares Fast Track and RMAT designations, Conditional marketing authorisation (EU), Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Regulatory divergence between regions and the tag law.
- TermFDORA 2022 accelerated approval reforms
Shares Japan conditional early approval and time-limited approval, Conditional marketing authorisation (EU), Accelerated approval and the tag law.
- Term21st Century Cures Act
Shares Fast Track and RMAT designations, Accelerated approval and the tag law.
- TermFederal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments
Shares Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Accelerated approval, Regulatory divergence between regions and the tag law.
- TermMedicines and Medical Devices Act 2021
Shares Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA), Regulatory divergence between regions and the tag law.